Frontiers Lu-177-PSMA dosimetry for kidneys and tumors based on SPECT images at two imaging time points

Patient-specific dosimetry adapted to variable number of SPECT/CT

Frontiers Towards Routine Clinical Use of Dosimetry in [177Lu]Lu

Lutetium-177 prostate-specific membrane antigen (PSMA

Imaging-guided targeted radionuclide tumor therapy: From concept

Patient-specific dosimetry adapted to variable number of SPECT/CT

Sample kidneys (yellow) and tumor (green) maps delineated on CT

Tumor & Organ Dosimetry From Sequential Quantitative SPECT/CT

Low cost, high temporal resolution optical fiber-based γ-photon

225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic

Pharmaceuticals, Free Full-Text

Development of 177Lu-scFvD2B as a Potential Immunotheranostic

177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand